Zoetis Inc. (NYSE:ZTS) Shares Sold by Sachetta LLC

Sachetta LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.8% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 1,810 shares of the company’s stock after selling 53 shares during the quarter. Sachetta LLC’s holdings in Zoetis were worth $330,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Focus Financial Network Inc. ADV purchased a new position in shares of Zoetis in the 4th quarter worth $2,159,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after purchasing an additional 3,244,074 shares in the last quarter. Axiom Investors LLC DE grew its holdings in shares of Zoetis by 36.3% during the 4th quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock worth $117,331,000 after purchasing an additional 158,459 shares during the period. Global Assets Advisory LLC acquired a new stake in Zoetis during the 1st quarter worth approximately $8,831,000. Finally, Franklin Street Advisors Inc. NC raised its holdings in Zoetis by 4.3% in the first quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock valued at $20,478,000 after buying an additional 5,035 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 1.3 %

Shares of ZTS opened at $191.73 on Tuesday. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The stock has a 50-day moving average price of $181.60 and a 200 day moving average price of $174.36. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The company has a market capitalization of $86.86 billion, a P/E ratio of 36.94, a P/E/G ratio of 2.90 and a beta of 0.88.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s revenue was up 8.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.41 EPS. Sell-side analysts forecast that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on ZTS shares. Stifel Nicolaus reissued a “buy” rating and issued a $200.00 price objective on shares of Zoetis in a research report on Tuesday, August 27th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler boosted their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Finally, BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $217.11.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.